Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

Non-small cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Some recurrent tumors have a comm...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kwak, Eunice L., Sordella, Raffaella, Bell, Daphne W., Godin-Heymann, Nadia, Okimoto, Ross A., Brannigan, Brian W., Harris, Patricia L., Driscoll, David R., Fidias, Panos, Lynch, Thomas J., Rabindran, Sridhar K., McGinnis, John P., Wissner, Allan, Sharma, Sreenath V., Isselbacher, Kurt J., Settleman, Jeffrey, Haber, Daniel A.
Format: Artigo
Jezik:Inglês
Izdano: National Academy of Sciences 2005
Teme:
Biological Sciences
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1129023/
https://ncbi.nlm.nih.gov/pubmed/15897464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0502860102
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items